India's Marksans Pharma gains as US FDA completes inspection at unit
30/06/2025 09:51
** India's Marksans Pharma MARK.NS gains 3.1% to 260.60 rupees ** US FDA finishes inspection at drugmaker's manufacturing facility in New York with no observations ** MARK also gets establishment inspection report from US FDA - showing successful completion of inspection ** Stock trims YTD losses to 12% (Reporting by Kashish Tandon in Bengaluru) ((Kashish.tandon@thomsonreuters.com))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg